MBT/Pas mouse: a relevant model for the evaluation of Rift Valley fever vaccines

• DOI: 10.1099/vir.0.042754-0
• Publication Date: 2012-04-19T07:02:33Z
• Authors: Emna Ayari-Fakhfakh; Tânia Zaverucha d...; Laurent Guillemot; Jean-Jacques Pant...; Michèle Bouloy; Abdeljelil Ghram; Emmanuel Albina; Catherine Cêtre-S...
• Keywords: vaccin; contrôle de maladies; Rift Valley Fever; Drug Evaluation, Preclinical; souris; L73 - Maladies des animaux; modèle; testage; Mice; http://aims.fao.org/aos/agrovoc/c_2491; MESH: Rift Valley Fever; MESH: Animals; http://aims.fao.org/aos/agrovoc/c_4795; 0303 health sciences; http://aims.fao.org/aos/agrovoc/c_2327; Vaccination; http://aims.fao.org/aos/agrovoc/c_24554; Preclinical; 3. Good health; http://aims.fao.org/aos/agrovoc/c_16463; MESH: Drug Evaluation, Preclinical; MESH: Rift Valley fever virus; Female; 570; 610; Virus de la fièvre de la vallée du Rift; Vaccines, Attenuated; 03 medical and health sciences; vaccin vivant; MESH: Viral Vaccines; MESH: Vaccines, Attenuated; Animals; Humans; http://aims.fao.org/aos/agrovoc/c_8130; http://aims.fao.org/aos/agrovoc/c_7683; http://aims.fao.org/aos/agrovoc/c_b08d44fd; MESH: Mice; MESH: Drug Evaluation; MESH: Humans; Animal; fièvre de la Vallée du Rift; Viral Vaccines; MESH: Vaccination; Rift Valley fever virus; MESH: Vaccines; http://aims.fao.org/aos/agrovoc/c_4881; http://aims.fao.org/aos/agrovoc/c_8007; Disease Models, Animal; Attenuated; efficacité; [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie; MESH: Disease Models; MESH: Disease Models, Animal; MESH: Female

Currently, there are no worldwide licensed vaccines for Rift Valley fever (RVF) that are both safe and effective. Development and evaluation of vaccines, diagnostics and treatments depend on the availability of appropriate animal models. Animal models are also necessary to understand the basic pathobiology of infection. Here, we report the use of an inbred MBT/Pas mouse model that consistently reproduces RVF disease and serves our purpose for testing the efficacy of vaccine candidates; an attenuated Rift Valley fever virus (RVFV) and a recombinant RVFV–capripoxvirus. We show that this model is relevant for vaccine testing.